The proposed mechanism is that elevated serum levels of FGF23 lead to left ventricular hypertrophy and endothelial dysfunction, worsening arterial stiffness, and accelerated cardiovascular damage in patients with CKD24–29. Here, FGF23 is linked to endothelial dysfunction.